Marinomed Biotech AG (WBO:MARI) Total Assets : €14.61 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Marinomed Biotech AG Total Assets?

Marinomed Biotech AG's Total Assets for the quarter that ended in Dec. 2023 was €14.61 Mil.

Warning Sign:

If a company builds assets at 26% a year, faster than its revenue growth rate of 9.9% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Marinomed Biotech AG's average Total Assets Growth Rate was -14.80% per year. During the past 3 years, the average Total Assets Growth Rate was -5.60% per year. During the past 5 years, the average Total Assets Growth Rate was 26.00% per year.

During the past 9 years, Marinomed Biotech AG's highest 3-Year average Total Assets Growth Rate was 63.60%. The lowest was -5.60%. And the median was 30.25%.

Total Assets is connected with ROA %. Marinomed Biotech AG's annualized ROA % for the quarter that ended in Dec. 2023 was -31.99%. Total Assets is also linked to Revenue through Asset Turnover. Marinomed Biotech AG's Asset Turnover for the quarter that ended in Dec. 2023 was 0.14.

Marinomed Biotech AG Total Assets Historical Data

The historical data trend for Marinomed Biotech AG's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinomed Biotech AG Total Assets Chart

Marinomed Biotech AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

19.50

23.50

21.34

22.29

14.61

Marinomed Biotech AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															22.29	19.48	17.84	15.17	14.61

Marinomed Biotech AG Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Marinomed Biotech AG's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-10.136	+	24.748
	=	14.61

Marinomed Biotech AG's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-10.136	+	24.748
	=	14.61

Marinomed Biotech AG (WBO:MARI) Total Assets Explanation

Total Assets is connected with ROA %.

Marinomed Biotech AG's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-4.764	/	( (15.171	+	14.612)	/ 2 )
	=	-4.764	/	14.8915
	=	-31.99 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Marinomed Biotech AG's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	2.027	/	( (15.171	+	14.612)	/ 2 )
=	2.027	/	14.8915
=	0.14

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Marinomed Biotech AG Total Assets Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinomed Biotech AG (WBO:MARI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (WBO:MARI) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

93Z:Germany

Address

Hovengasse 25, Korneuburg, AUT, 2100

Website

https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generates from the virology segment.

Marinomed Biotech AG (WBO:MARI) Headlines

No Headlines